Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis
Get Alerts REGN Hot Sheet
Price: $959.92 -0.47%
Rating Summary:
29 Buy, 13 Hold, 1 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 20 | Down: 14 | New: 22
Rating Summary:
29 Buy, 13 Hold, 1 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 20 | Down: 14 | New: 22
Join SI Premium – FREE
Citi maintains a 'Neutral' on Regeneron Pharma (NASDAQ: REGN) price target of $68.
Analyst, Yaron Werber, suggested that recent channel checks indicate doctors are really considering switching to REGN's Eylea from Roche's (OTC: RHHBY) Lucentis, citing: 1) cut in price; 2) lower dosing amounts, but better potency; and 3) signs Eylea is working more effectively on certain patients.
Shares of REGN are trading near session highs, up $4.38 (+4.52%) to $101.24 (new 52-wk high). However, the stock has moved up from the mid-$30 level to over $100 in the past 52-wks.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $96.86 yesterday.
Analyst, Yaron Werber, suggested that recent channel checks indicate doctors are really considering switching to REGN's Eylea from Roche's (OTC: RHHBY) Lucentis, citing: 1) cut in price; 2) lower dosing amounts, but better potency; and 3) signs Eylea is working more effectively on certain patients.
Shares of REGN are trading near session highs, up $4.38 (+4.52%) to $101.24 (new 52-wk high). However, the stock has moved up from the mid-$30 level to over $100 in the past 52-wks.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $96.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIU Technologies (NIU) PT Lowered to $2 at Citi
- Darden Restaurants (DRI) PT Raised to $190 at Stifel
- Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!